Delisting risk
Apimeds Pharmaceuticals US
Developing a bee-venom knee-osteoarthritis therapy and Bitcoin-treasury infrastructure.
$3.87
After-hours close−0.01 (−0.26%)
At close$3.88(−1.77%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 2.97%Insiders —
Shares outstanding 1.51M · Float 563.2K · 37.3% free float
A split settled inside the quarter being compared, so quarter-on-quarter change is not shown.
Institutions13F, as of Mar 31, 2026
6 holders · 44.9K shares
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Hemenway Trust Co LLC | 27.4K | 1.82% | May 7, 2026 | |
| Vanguard Capital Management LLC | 9.6K | 0.64% | May 15, 2026 | |
| Geode Capital Management, LLC | 4.0K | 0.27% | May 15, 2026 | |
| Vanguard Fiduciary Trust Co | 2.4K | 0.16% | May 8, 2026 | |
| Two Sigma Securities, LLC | 1.1K | 0.07% | May 15, 2026 | |
| UBS Group AG | 419 | 0.03% | May 5, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Apimeds Inc.incl. Inscobee Inc. | 34.30% | 13D | May 7, 2026 ↗ | |
| Ayrton Capital LLC | 9.99% | 13G | Feb 11, 2026 ↗ |
InsidersForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.